Intravitreal Clindamycin and Dexamethasone Combined with Systemic Oral Antitoxoplasma Therapy versus Intravitreal Therapy Alone in the Management of Toxoplasma Retinochoroiditis: A Retrospective Study
Purpose. To compare clinical outcome of IVCD combined with oral therapy with IVCD alone in patients with toxoplasmic retinochoroiditis. Patients and Methods. Thirty eyes were reviewed. Two equal groups were identified (15 eyes each). Clinical outcome measures were resolution of active inflammation,...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-01-01
|
| Series: | Journal of Ophthalmology |
| Online Access: | http://dx.doi.org/10.1155/2018/4160837 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832553418415144960 |
|---|---|
| author | Ashraf Bor’i Ashraf Mahrous Mahmoud A. Al-Aswad Haitham Y. Al-Nashar Waled M. Nada Mostafa Wagih Ahmed M. B. Awad Wael M. El-Haig |
| author_facet | Ashraf Bor’i Ashraf Mahrous Mahmoud A. Al-Aswad Haitham Y. Al-Nashar Waled M. Nada Mostafa Wagih Ahmed M. B. Awad Wael M. El-Haig |
| author_sort | Ashraf Bor’i |
| collection | DOAJ |
| description | Purpose. To compare clinical outcome of IVCD combined with oral therapy with IVCD alone in patients with toxoplasmic retinochoroiditis. Patients and Methods. Thirty eyes were reviewed. Two equal groups were identified (15 eyes each). Clinical outcome measures were resolution of active inflammation, changes in BCVA and CMT, adverse drug reactions, and rate of recurrence. Results. Mean baseline of BCVA 1.08 ± 0.17 and 1.03 ± 0.15 improved to 0.64 ± 0.18 and 0.69 ± 0.17 at the end of follow-up in group I and II, respectively. No statistically significant difference was observed. CMT was 392.6 ± 33.16 μm and 397.3 ± 14.6 μm significantly decreased to 314.7 ± 4.43 μm and 319.6 ± 7.8 μm. Resolution of acute inflammation was achieved in all cases in both groups. There were no recurrent cases in group I, and only one out of 15 (6.7%) in group II. No ocular or systemic adverse events were recorded. Conclusion. IVCD is an effective route of treatment for active toxoplasmic retinochoroiditis that can be used solely without the need to use systemic medications.. |
| format | Article |
| id | doaj-art-b03c0f2c7adb4f20912d1da39fabe4c3 |
| institution | Kabale University |
| issn | 2090-004X 2090-0058 |
| language | English |
| publishDate | 2018-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Ophthalmology |
| spelling | doaj-art-b03c0f2c7adb4f20912d1da39fabe4c32025-02-03T05:54:04ZengWileyJournal of Ophthalmology2090-004X2090-00582018-01-01201810.1155/2018/41608374160837Intravitreal Clindamycin and Dexamethasone Combined with Systemic Oral Antitoxoplasma Therapy versus Intravitreal Therapy Alone in the Management of Toxoplasma Retinochoroiditis: A Retrospective StudyAshraf Bor’i0Ashraf Mahrous1Mahmoud A. Al-Aswad2Haitham Y. Al-Nashar3Waled M. Nada4Mostafa Wagih5Ahmed M. B. Awad6Wael M. El-Haig7Department of Ophthalmology, Zagazig University, Zagazig, EgyptDepartment of Ophthalmology, Zagazig University, Zagazig, EgyptDepartment of Ophthalmology, Zagazig University, Zagazig, EgyptDepartment of Ophthalmology, Zagazig University, Zagazig, EgyptDepartment of Ophthalmology, Zagazig University, Zagazig, EgyptDepartment of Ophthalmology, Zagazig University, Zagazig, EgyptDepartment of Ophthalmology, Zagazig University, Zagazig, EgyptDepartment of Ophthalmology, Zagazig University, Zagazig, EgyptPurpose. To compare clinical outcome of IVCD combined with oral therapy with IVCD alone in patients with toxoplasmic retinochoroiditis. Patients and Methods. Thirty eyes were reviewed. Two equal groups were identified (15 eyes each). Clinical outcome measures were resolution of active inflammation, changes in BCVA and CMT, adverse drug reactions, and rate of recurrence. Results. Mean baseline of BCVA 1.08 ± 0.17 and 1.03 ± 0.15 improved to 0.64 ± 0.18 and 0.69 ± 0.17 at the end of follow-up in group I and II, respectively. No statistically significant difference was observed. CMT was 392.6 ± 33.16 μm and 397.3 ± 14.6 μm significantly decreased to 314.7 ± 4.43 μm and 319.6 ± 7.8 μm. Resolution of acute inflammation was achieved in all cases in both groups. There were no recurrent cases in group I, and only one out of 15 (6.7%) in group II. No ocular or systemic adverse events were recorded. Conclusion. IVCD is an effective route of treatment for active toxoplasmic retinochoroiditis that can be used solely without the need to use systemic medications..http://dx.doi.org/10.1155/2018/4160837 |
| spellingShingle | Ashraf Bor’i Ashraf Mahrous Mahmoud A. Al-Aswad Haitham Y. Al-Nashar Waled M. Nada Mostafa Wagih Ahmed M. B. Awad Wael M. El-Haig Intravitreal Clindamycin and Dexamethasone Combined with Systemic Oral Antitoxoplasma Therapy versus Intravitreal Therapy Alone in the Management of Toxoplasma Retinochoroiditis: A Retrospective Study Journal of Ophthalmology |
| title | Intravitreal Clindamycin and Dexamethasone Combined with Systemic Oral Antitoxoplasma Therapy versus Intravitreal Therapy Alone in the Management of Toxoplasma Retinochoroiditis: A Retrospective Study |
| title_full | Intravitreal Clindamycin and Dexamethasone Combined with Systemic Oral Antitoxoplasma Therapy versus Intravitreal Therapy Alone in the Management of Toxoplasma Retinochoroiditis: A Retrospective Study |
| title_fullStr | Intravitreal Clindamycin and Dexamethasone Combined with Systemic Oral Antitoxoplasma Therapy versus Intravitreal Therapy Alone in the Management of Toxoplasma Retinochoroiditis: A Retrospective Study |
| title_full_unstemmed | Intravitreal Clindamycin and Dexamethasone Combined with Systemic Oral Antitoxoplasma Therapy versus Intravitreal Therapy Alone in the Management of Toxoplasma Retinochoroiditis: A Retrospective Study |
| title_short | Intravitreal Clindamycin and Dexamethasone Combined with Systemic Oral Antitoxoplasma Therapy versus Intravitreal Therapy Alone in the Management of Toxoplasma Retinochoroiditis: A Retrospective Study |
| title_sort | intravitreal clindamycin and dexamethasone combined with systemic oral antitoxoplasma therapy versus intravitreal therapy alone in the management of toxoplasma retinochoroiditis a retrospective study |
| url | http://dx.doi.org/10.1155/2018/4160837 |
| work_keys_str_mv | AT ashrafbori intravitrealclindamycinanddexamethasonecombinedwithsystemicoralantitoxoplasmatherapyversusintravitrealtherapyaloneinthemanagementoftoxoplasmaretinochoroiditisaretrospectivestudy AT ashrafmahrous intravitrealclindamycinanddexamethasonecombinedwithsystemicoralantitoxoplasmatherapyversusintravitrealtherapyaloneinthemanagementoftoxoplasmaretinochoroiditisaretrospectivestudy AT mahmoudaalaswad intravitrealclindamycinanddexamethasonecombinedwithsystemicoralantitoxoplasmatherapyversusintravitrealtherapyaloneinthemanagementoftoxoplasmaretinochoroiditisaretrospectivestudy AT haithamyalnashar intravitrealclindamycinanddexamethasonecombinedwithsystemicoralantitoxoplasmatherapyversusintravitrealtherapyaloneinthemanagementoftoxoplasmaretinochoroiditisaretrospectivestudy AT waledmnada intravitrealclindamycinanddexamethasonecombinedwithsystemicoralantitoxoplasmatherapyversusintravitrealtherapyaloneinthemanagementoftoxoplasmaretinochoroiditisaretrospectivestudy AT mostafawagih intravitrealclindamycinanddexamethasonecombinedwithsystemicoralantitoxoplasmatherapyversusintravitrealtherapyaloneinthemanagementoftoxoplasmaretinochoroiditisaretrospectivestudy AT ahmedmbawad intravitrealclindamycinanddexamethasonecombinedwithsystemicoralantitoxoplasmatherapyversusintravitrealtherapyaloneinthemanagementoftoxoplasmaretinochoroiditisaretrospectivestudy AT waelmelhaig intravitrealclindamycinanddexamethasonecombinedwithsystemicoralantitoxoplasmatherapyversusintravitrealtherapyaloneinthemanagementoftoxoplasmaretinochoroiditisaretrospectivestudy |